US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Champion Industries, Inc.

0.0200

0.0000

Volume:- -

Turnover:- -

Market Cap:1.12K

PE:0.00

High:0.0200

Open:0.0200

Low:0.0200

Close:0.0200

52wk High:0.0200

52wk Low:0.0001

Shares:55.86K

Float Shares:- -

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-23.0334

EPS(LYR):-23.0334

ROE:-49.45%

ROA:-1.87%

PB:0.00

PE(LYR):0.00

Loading ...

Overview Company News Filings

How WINREVAIR’s Expanded CHMP-Backed PAH Indication At Merck (MRK) Has Changed Its Investment Story

Simply Wall St.

European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Press Release: Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Biogen Gets CHMP Backing for Higher-Dose Spinraza

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

Incyte announces CHMP opinion recommending approval of Minjuvi combination

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

Anavex Faces CHMP Setback for Alzheimer’s Drug

Ionis Pharmaceuticals announces CHMP opinion recommending Dawnzera approval

Press Release: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

Gan&Lee Pharmaceuticals (603087.SH): CHMP Grants Positive Opinion for Marketing Authorization Application (MAA) of Insulin Glargine Injection (Ondibta®) in EU

Ascendis Pharma Reports Third Quarter 2025 Financial Results

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

CStone Pharmaceuticals (SEHK:2616): Valuation in Focus After Landmark CHMP Nod and Pipeline Breakthroughs

Simply Wall St.

GSK’s Shingrix Prefilled Syringe Gains Positive CHMP Opinion

Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHMP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"Champion Industries, Inc.","latestPrice":0.02,"timestamp":1772571600000,"preClose":0.02,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"Not Yet Opened","change":0,"latestTime":"03-03 16:00:00 EST Delay","open":0.02,"high":0.02,"low":0.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772614800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.02,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","floatShares":0,"roa":"-1.87%","roe":"-49.45%","lyrEps":-23.033406,"shares":55857,"dividePrice":0,"high":0.02,"amplitude":0,"preClose":0.02,"low":0.02,"week52Low":0.0001,"pbRate":"0.00","psRate":"0.00","week52High":0.02,"institutionHeld":0,"latestPrice":0.02,"eps":-23.033406,"divideRate":0,"volume":0,"delay":15,"ttmEps":-23.033406,"open":0.02,"prevYearClose":0.02,"prevWeekClose":0.02,"prevMonthClose":0.02,"prevQuarterClose":0.02,"fiveDayClose":0.02,"twentyDayClose":0.02,"sixtyDayClose":0.0001},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHMP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHMP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHMP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2591922662","title":"How WINREVAIR’s Expanded CHMP-Backed PAH Indication At Merck (MRK) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2591922662","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591922662?lang=en_us&edition=fundamental","pubTime":"2025-12-15 04:19","pubTimestamp":1765743562,"startTime":"0","endTime":"0","summary":"Merck recently reported that the European Medicines Agency’s CHMP has recommended expanding WINREVAIR’s pulmonary arterial hypertension indication in Europe to include higher-risk WHO Functional Class II–IV adults, following strong Phase 3 ZENITH data on morbidity and mortality outcomes.\nThis regulatory momentum strengthens WINREVAIR’s position as a differentiated activin signaling inhibitor in a serious disease area, potentially broadening its role as one of Merck’s key growth drivers...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/288502-main-header/1756255043815","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/288502-main-header/1756255043815"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mrk/merck/news/how-winrevairs-expanded-chmp-backed-pah-indication-at-merck","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mrk/merck/news/how-winrevairs-expanded-chmp-backed-pah-indication-at-merck","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1934455863.HKD","LU0006306889.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD","LU0234572021.USD","BK4533","LU1093756325.SGD","LU1162221912.USD","SG9999015358.SGD","LU1983299246.USD","BK4588","SG9999014567.USD","LU0980610538.SGD","LU0130517989.USD","LU0070302665.USD","SG9999014559.SGD","BK4087","LU0122379950.USD","LU1023059063.AUD","LU1093756168.USD","LU2023250843.SGD","LU0965508806.USD","LU0058720904.USD","BK4559","LU1929549753.HKD","SG9999002224.SGD","LU0965509010.AUD","LU1057294990.SGD","LU2089984988.USD","BK4550","SGXZ57979304.SGD","LU1291159041.SGD","LU1941712348.USD","CHMP","LU0106261372.USD","SG9999014542.SGD","SG9999013999.USD","LU1699723380.USD","LU2360032135.SGD","LU1934455277.USD","LU1934455194.USD","LU2324357040.USD","MRK","BK4534","LU0477156953.USD","LU0985320562.USD","LU1066051225.USD","LU1989772923.USD","SG9999001176.SGD","LU2361044949.HKD"],"gpt_icon":0},{"id":"2591384686","title":"European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2591384686","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591384686?lang=en_us&edition=fundamental","pubTime":"2025-12-13 02:55","pubTimestamp":1765565700,"startTime":"0","endTime":"0","summary":"On Friday, the European Medicines Agency's  Committee for Medicinal Products for Human Use  issued a positive opinion for Novo Nordisk A/S’  higher dose of Wegovy .Also Read: FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch. The new dose of Wegovy has demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity who do not have diabetes.These substantial weight loss results complement the already established health benefits of Wegovy in obesity-related complications, including a significant reduction in the risk of cardiovascular events such as heart attack and stroke, and a reduction in pain from knee osteoarthritis.In people with obesity and without diabetes, one in three participants treated with Wegovy achieved 25% or more weight loss at 72 weeks, with a safety and tolerability profile consistent with the approved Wegovy 2.4 mg semaglutide dose.Data showed that the majority (84%) of the weight lost with Wegovy came from fat mass loss","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/12/Siegen--North-Rhine-Westphalia---Germany.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/12/Siegen--North-Rhine-Westphalia---Germany.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/12/49371241/european-regulator-backs-approval-of-novo-nordisk-high-dose-wegovy","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49371241/european-regulator-backs-approval-of-novo-nordisk-high-dose-wegovy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0154236417.USD","LU1093756325.SGD","EMA","BK4588","IE00BKVL7J92.USD","BK4532","NVO","BK4585","LU1093756168.USD","BK4087","BK4081","IE00BZ1G4Q59.USD","CHMP","BK4007","BK4599"],"gpt_icon":1},{"id":"2588276470","title":"The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN","url":"https://stock-news.laohu8.com/highlight/detail?id=2588276470","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588276470?lang=en_us&edition=fundamental","pubTime":"2025-12-04 06:05","pubTimestamp":1764799500,"startTime":"0","endTime":"0","summary":"Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 depositsConsistent r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3199410/0/en/The-New-England-Journal-of-Medicine-Publishes-Positive-Phase-3-VALIANT-Results-of-EMPAVELI-pegcetacoplan-for-C3G-and-Primary-IC-MPGN.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA","BK4087","CHMP"],"gpt_icon":0},{"id":"2586755564","title":"Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®","url":"https://stock-news.laohu8.com/highlight/detail?id=2586755564","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586755564?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:10","pubTimestamp":1764076200,"startTime":"0","endTime":"0","summary":"Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194303/0/en/Teva-receives-European-Commission-approvals-for-PONLIMSI-denosumab-Biosimilar-to-Prolia-and-DEGEVMA-denosumab-Biosimilar-to-Xgeva.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","EC","BK4201","BK4087"],"gpt_icon":0},{"id":"2586647852","title":"Press Release: Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2586647852","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586647852?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:30","pubTimestamp":1764073800,"startTime":"0","endTime":"0","summary":"Company to host a webcast today at 8:30 a.m. Eastern Time. NEW YORK, Nov. 25, 2025  -- Anavex Life Sciences Corp.  , a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system  disorders, today reported financial results for its fourth quarter of fiscal 2025.\"There are currently an estimated 7.2 million people living with Alzheimer's disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally, targeted upstream medicines, particularly in the context of early Alzheimer's disease,\" said Christopher U. Missling, PhD, President and CEO of Anavex. \"Our clinical pipeline positions Anavex to address critical unmet needs in neurodegenerative and neurodevelopmental disorders with convenient and scalable therapeutic options. Oral blarcamesine demonstrated cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAA","BK4135","EMA","CHMP","CNS","BK4022","BK4087","AVXL","BK4585","R","BK4232","BK4588","BK4215","BK4081"],"gpt_icon":0},{"id":"2584864704","title":"Biogen Gets CHMP Backing for Higher-Dose Spinraza","url":"https://stock-news.laohu8.com/highlight/detail?id=2584864704","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584864704?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:40","pubTimestamp":1763379600,"startTime":"0","endTime":"0","summary":"Biogen said a key European regulatory committee has recommended approval of a high-dose regimen of its Spinraza drug for the neuromuscular disease spinal muscular atrophy, or SMA.Biogen on Monday said the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use covers the high-dose regimen of Spinraza for the treatment of 5q SMA, which represents about 95% of all SMA cases.The European Commission, which generally follows CHMP's advice, will now review the recommendation, with a decision expected in January, the Cambridge, Mass., biotechnology company said.The U.S. Food and Drug Administration is reviewing Biogen's application for the high-dose regimen, with a decision due by early April.Spinal muscular atrophy is a rare genetic disease characterized by a loss of motor neurons in the spinal cord and lower brain stem, resulting in severe, progressive muscle atrophy and weakness.Spinraza generated worldwide sales of $1.19 billion for the first n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00B894F039.SGD","BK4532","IONS","IE00B19Z9Z06.USD","BIIB","BK4087","LU0889565916.HKD","BK4533","BK4139","CHMP","LU0234570918.USD","LU0320765992.SGD","BK4585","BK4588","IE00B19Z9P08.USD"],"gpt_icon":0},{"id":"2584642687","title":"High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2584642687","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584642687?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377200,"startTime":"0","endTime":"0","summary":"Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/17/3188941/0/en/High-Dose-Regimen-of-Nusinersen-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-Spinal-Muscular-Atrophy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","BK4086","LU0054578231.USD","LU1815336091.USD","LU2125910179.SGD","BK4217","LU1169589451.USD","LU0106261612.USD","SMA","LU2413665964.HKD","WMS","LU1923621640.USD","LU0757428866.USD","BK4081","LU0728928796.USD","IE00BN0W2W23.USD","LU2413666004.HKD","LU1165135440.EUR","LU2308191902.HKD","LU2089279066.USD","IE00BN0W2T93.GBP","LU1721427968.SGD","LU1620156213.USD","IE00BN0W2V16.EUR","LU0012050646.USD","BK4087","LU1620156130.USD","LU2229751404.USD","LU1596574779.USD","LU1543694498.USD","EMA","LU1169590202.USD","LU2125910336.SGD"],"gpt_icon":0},{"id":"2584642833","title":"Incyte announces CHMP opinion recommending approval of Minjuvi combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2584642833","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584642833?lang=en_us&edition=fundamental","pubTime":"2025-11-17 18:45","pubTimestamp":1763376314,"startTime":"0","endTime":"0","summary":"Incyte (INCY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued an opinion recommending...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/incyte-announces-chmp-opinion-recommending-approval-of-minjuvi-combination-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/incyte-announces-chmp-opinion-recommending-approval-of-minjuvi-combination-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4087","BK4532","BK4588","BK4585","CHMP","BK4550","INCY"],"gpt_icon":0},{"id":"2583682450","title":"Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682450","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682450?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:05","pubTimestamp":1763154300,"startTime":"0","endTime":"0","summary":"– Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/14/3188609/0/en/Verrica-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCC","BK4080","BK4567","BK4081","BK4087","BK4104","SITC","BK4231","EMA","CHMP"],"gpt_icon":0},{"id":"2583506963","title":"Anavex Faces CHMP Setback for Alzheimer’s Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506963","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506963?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:58","pubTimestamp":1763125081,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences ( ($AVXL) ) has issued an update. On November 14, 2025, Anavex Life Sciences announced that the Committee for Medicinal Produc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/anavex-faces-chmp-setback-for-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/anavex-faces-chmp-setback-for-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHMP","BK4087"],"gpt_icon":0},{"id":"2583506953","title":"Ionis Pharmaceuticals announces CHMP opinion recommending Dawnzera approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506953","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506953?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:46","pubTimestamp":1763124391,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals (IONS) and Otsuka Pharmaceutical announced that the Committee for Medicinal Products for Human Use of the European Medicines ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ionis-pharmaceuticals-announces-chmp-opinion-recommending-dawnzera-approval-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ionis-pharmaceuticals-announces-chmp-opinion-recommending-dawnzera-approval-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHMP","BK4139","IONS","BK4087"],"gpt_icon":0},{"id":"2583566564","title":"Press Release: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583566564","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583566564?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:50","pubTimestamp":1763034600,"startTime":"0","endTime":"0","summary":"Company to host conference call and webcast today at 8:00 a.m. EST. CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update.\"We are pleased to report total revenues of $43.6 million for the first nine months of 2025, an increase of 24%, compared to the same period in 2024. Our total revenues for the third quarter were $17.9 million which reflects a decrease of 1%, compared to revenues for the same period of 2024,\" said Dror Bashan, Protalix's President and Chief Executive Officer. \"We recognize revenues from sales of our products to Chiesi, Pfizer, and Fiocruz in Brazil, and their purchases vary from quarter to quarter as they control their ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","SG9999011175.SGD","BK4534","LU0058720904.USD","SG9999002224.SGD","LU0122379950.USD","BK4599","BK4568","LU1066051498.USD","LU0225771236.USD","BK4581","LU1883839398.USD","LU1894683264.USD","IE00B19Z3B42.SGD","LU0225284248.USD","LU0170899867.USD","BK4592","LU0321505439.SGD","BK4007","SGXZ57979304.SGD","IE00BBT3K403.USD","LU1894683348.USD","LU0306807586.USD","SG9999002232.USD","BK4139","LU1066053197.SGD","LU0321505868.SGD","R","LU1057294990.SGD","SG9999003800.SGD","LU0289739699.SGD","IE000M9KFDE8.USD","EMA","IE0002270589.USD","LU0456855351.SGD","LU0234572021.USD","BK4533","BK4022","SG9999001176.SGD","SG9999013999.USD","BK4081","PLX","CHMP","IE00B19Z3581.USD","SG9999001176.USD","LU0868494617.USD","BK4585","LU0985481810.HKD","LU0306806265.USD"],"gpt_icon":1},{"id":"1189004134","title":"Gan&Lee Pharmaceuticals (603087.SH): CHMP Grants Positive Opinion for Marketing Authorization Application (MAA) of Insulin Glargine Injection (Ondibta®) in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=1189004134","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189004134?lang=en_us&edition=fundamental","pubTime":"2025-11-13 17:20","pubTimestamp":1763025640,"startTime":"0","endTime":"0","summary":"Gan&Lee Pharmaceuticals (603087.SH) announced that the company and its wholly-owned European subsidiary, Gan&Lee Pharmaceuticals Europe GmbH, recently received notification from the European...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","BK0239","FESXmain","CHMP","BK4585","BK4588","FSXEmain","603087","MAA","BK4087"],"gpt_icon":0},{"id":"2583007873","title":"Ascendis Pharma Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583007873","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583007873?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:01","pubTimestamp":1762981260,"startTime":"0","endTime":"0","summary":"– Q3 2025 revenue of 143.1 million for YORVIPATH and 50.7 million for SKYTROFA – Q3 2025 operating profit of 11.0 million – TransCon CNP (navepegritide) under FDA Priority Review for the treatment of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186726/0/en/Ascendis-Pharma-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","BK4561","BK4007","BK4097","SGA","BK4590","BK4087","BK4588","ET","OS","MAA","BK4581","PROC","BK4215","BK4585","BK4125","BK4144"],"gpt_icon":0},{"id":"2581726270","title":"Ocugen Provides Business Update with Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581726270","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581726270?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:30","pubTimestamp":1762342200,"startTime":"0","endTime":"0","summary":"Conference Call and Webcast Today at 8:30 a.m. ETPhase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181230/0/en/Ocugen-Provides-Business-Update-with-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","BK4563","MAA","BK4568","BK4215","BK4081","EMA","BK4139","BK4087","OCGN","BK4585","BK4588"],"gpt_icon":0},{"id":"2579170781","title":"Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2579170781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579170781?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:05","pubTimestamp":1761822300,"startTime":"0","endTime":"0","summary":"Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI (pegcetacoplan) in the first two months since launch in C3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177251/0/en/Apellis-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0390134368.USD","IE00B5949003.HKD","BK4554","FSGS","LU0109392836.USD","LU0823421333.USD","LU1064131342.USD","LU1242518931.SGD","LU1951198990.SGD","LU0056508442.USD","CHMP","LU0979878070.USD","LU2360106780.USD","BK4566","LU1803068979.SGD","LU0127658192.USD","IE0004445239.USD","LU1861558580.USD","LU0889565833.HKD","EMA","BK4585","LU0719512351.SGD","LU1880398554.USD","BK4573","LU1880398471.USD","LU1951200564.SGD","LU2250418816.HKD","LU0823434740.USD","BK4575","LU2054465674.USD","BK4087","LU1303367103.USD","BK4529","LU1316542783.SGD","IE0009356076.USD","BK4141","LU2458330169.SGD","BK4534","LU0823434583.USD","LU0082616367.USD","BK4532","BK4543","LU1988902786.USD","LU0642271901.SGD","LU0823421416.USD","LU2098885051.SGD","BK4512","LU1852331112.SGD","LU1242518857.USD"],"gpt_icon":1},{"id":"2579114441","title":"Agios Reports Third Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2579114441","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579114441?lang=en_us&edition=fundamental","pubTime":"2025-10-30 18:30","pubTimestamp":1761820200,"startTime":"0","endTime":"0","summary":"$12.9 million in third quarter PYRUKYND (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia;","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177175/31990/en/Agios-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4087","BK4081","GCC","CHMP"],"gpt_icon":0},{"id":"2578630717","title":"CStone Pharmaceuticals (SEHK:2616): Valuation in Focus After Landmark CHMP Nod and Pipeline Breakthroughs","url":"https://stock-news.laohu8.com/highlight/detail?id=2578630717","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578630717?lang=en_us&edition=fundamental","pubTime":"2025-10-26 17:25","pubTimestamp":1761470729,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (SEHK:2616) is gaining attention after two key developments: a positive opinion from Europe’s drug regulator for sugemalimab in lung cancer, and fresh data on its early-stage immunotherapy candidates. Investors are watching closely.\nSee our latest analysis for CStone Pharmaceuticals.\nThe recent surge in CStone Pharmaceuticals’ share price, up nearly 158% year-to-date, reflects growing investor confidence on the back of regulatory wins and progress with its immunotherapy...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-in-focus-after-lan","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-in-focus-after-lan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","02616","BK4211","BK4087","BK1574","LARK","BK1161","CHMP"],"gpt_icon":0},{"id":"2577405845","title":"GSK’s Shingrix Prefilled Syringe Gains Positive CHMP Opinion","url":"https://stock-news.laohu8.com/highlight/detail?id=2577405845","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577405845?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:23","pubTimestamp":1761027806,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) has issued an announcement. GSK announced that the European Medicine Agency’s Committee for Medicinal Products for Hu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-shingrix-prefilled-syringe-gains-positive-chmp-opinion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-shingrix-prefilled-syringe-gains-positive-chmp-opinion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4087","LU1829250122.USD","CHMP","GSK","BK4585","GSK.UK","BK4007","BK4532","BK4588"],"gpt_icon":0},{"id":"2577895071","title":"Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577895071","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577895071?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:45","pubTimestamp":1760993112,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals (VRCA) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has provided feed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/verrica-pharmaceuticals-announces-chmp-support-for-ycanth-maa-filing-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/verrica-pharmaceuticals-announces-chmp-support-for-ycanth-maa-filing-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHMP","VRCA","BK4585","BK4087","MAA","BK4588","BK4007","BK4215"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":58,"code":"91000000","status":"200"}]}}